Cellectar Reports DLBCL Complete Response Lasting Over Eight Years

Cellectar said a heavily pretreated DLBCL patient had a complete response lasting over eight years after one iopofosine I 131 administration. The company expects to begin dosing its confirmatory Phase 3 WM study in Q1 2027 and targets an H1 2027 FDA filing.